Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III recombinant five-antigen Staphylococcus aureus vaccine trial in adults undergoing orthopedic surgery
ChiCTR2200062998Phase 3Not yet recruiting
- Sponsor
- Beijing Jishuitan Hospital
- Start
- Aug 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant five-antigen Staphylococcus aureus vaccine in Staphylococcus aureus infection (2 arms), sponsored by Beijing Jishuitan Hospital. Primary endpoint: Infection rate of Staphylococcus aureus after orthopedic surgery. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
recombinant five-antigen Staphylococcus aureus vaccine
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on ChiCTR2200062998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062998.